Along this line, the ex vivo analysis of RTX-treated DLBCL patients revealed a marked and prolonged therapy-induced reduction in both “natural” and CD16-dependent NK cytotoxic activities, accompanied by the down-modulation of CD16 and NKG2D, which is the activating receptor [24]. This evidence concerns the gene FCGR3A and diffuse large B-cell lymphoma.